TrialSignal
Clinical trial intelligence report
A Randomized, Placebo-controlled Study to Evaluate the Safety, Pharmacokinetics and Efficacy of a Single Dose of STI-2020 (COVI-AMG™) in Adults With Mild COVID-19 Symptoms
Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.
Generated
Jun 20, 2026
NCT ID
NCT04734860
Status
WITHDRAWN
Phase
Phase 2
Sponsor
Sorrento Therapeutics, Inc.
Executive brief
Investment-Ready Snapshot
Sorrento Therapeutics, Inc. initiated a randomized, placebo-controlled trial to evaluate the safety and efficacy of STI-2020 (COVI-AMG™), a neutralizing monoclonal antibody for adults with mild COVID-19 symptoms. The study was designed to assess pharmacokinetics and patient outcomes over a 70-day follow-up period.
Source & freshness
Provenance
https://clinicaltrials.gov/study/NCT04734860
Indication
Covid19
Modality
monoclonal antibody
Target
COVID-19
Intervention
COVI-AMG, Placebo
Source record
Protocol Description
Detailed source ingestion pending.
Source record
Outcome Measures
Detailed source ingestion pending.
Source record
Eligibility
Detailed source ingestion pending.
AI analysis
Known Results And Readout Context
Detailed source ingestion pending.
IP intelligence
Patent And IP Landscape
Detailed source ingestion pending.
Source record
Contacts
Detailed source ingestion pending.